Natera, Inc.

Equities

NTRA

US6323071042

Healthcare Facilities & Services

Market Closed - Nasdaq 21:00:00 10/05/2024 BST 5-day change 1st Jan Change
105.3 USD +10.19% Intraday chart for Natera, Inc. +8.57% +68.09%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Baird Adjusts Natera Price Target to $117 From $99, Maintains Outperform Rating MT
UBS Boosts Price Target on Natera to $160 From $104, Keeps Buy Rating MT
Top Premarket Gainers MT
Natera Q1 Loss Narrows, Revenue Rises; Full-Year Revenue Guidance Raised -- Shares Jump After Hours MT
Natera, Inc. Provides Earnings Guidance for the Year 2024 CI
Transcript : Natera, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (NTRA) NATERA Reports Q1 Revenue $367.7M, vs. Street Est of $315.3M MT
Natera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Natera, Inc. Announces a New Publication in JCO Precision Oncology Reporting on the Ability of its Personalised and Tumor-Informed Molecular Residual Disease Test, Signatera CI
Natera, Inc. Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage CI
Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing MT
Natera Insider Sold Shares Worth $634,797, According to a Recent SEC Filing MT
Goldman Sachs Adjusts Natera Price Target to $100 From $90, Maintains Buy Rating MT
Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation CI
Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients CI
North American Morning Briefing : Inflation Data, -2- DJ
Natera Reports Positive Surveillance Analysis From Phase 3 Study of Bladder Cancer Test; Shares Rise MT
Bernstein Upgrades Natera to Outperform From Market Perform, Raises Price Target to $120 From $86 MT
Natera Insider Sold Shares Worth $2,468,822, According to a Recent SEC Filing MT
Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer CI
Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera?? in Stage II Colorectal Cancer CI
Natera Insider Sold Shares Worth $534,331, According to a Recent SEC Filing MT
Natera Insider Sold Shares Worth $824,092, According to a Recent SEC Filing MT
Natera Insider Sold Shares Worth $16,694,485, According to a Recent SEC Filing MT
Natera Receives Commercial Insurance Coverage of Genetic Test for Transplant Risks MT
Chart Natera, Inc.
More charts
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
105.3 USD
Average target price
112.6 USD
Spread / Average Target
+6.99%
Consensus
  1. Stock Market
  2. Equities
  3. NTRA Stock
  4. News Natera, Inc.
  5. Goldman Sachs Adjusts Price Target on Natera to $80 From $64, Maintains Buy Rating